Drugs Containing Excipient (Inactive Ingredient) SODIUM PHOSPHATE, DIBASIC ANHYDROUS

Branded drugs containing SODIUM PHOSPHATE, DIBASIC ANHYDROUS excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dispensing Solutions Inc	XALATAN	latanoprost	68258-8976	SODIUM PHOSPHATE, DIBASIC ANHYDROUS

Generic drugs containing SODIUM PHOSPHATE, DIBASIC ANHYDROUS excipient

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	hydrocortisone valerate	21695-730	SODIUM PHOSPHATE, DIBASIC ANHYDROUS
Rebel Distributors Corp	latanoprost	21695-986	SODIUM PHOSPHATE, DIBASIC ANHYDROUS
Akorn - Strides LLC	vecuronium bromide	23360-160	SODIUM PHOSPHATE, DIBASIC ANHYDROUS
Physicians Total Care Inc	latanoprost	54868-6254	SODIUM PHOSPHATE, DIBASIC ANHYDROUS

Sodium Phosphate, Dibasic Anhydrous Market Dynamics and Financial Trajectory

Last updated: August 26, 2026

Sodium phosphate, dibasic anhydrous is a mature, low-cost pharmaceutical excipient used primarily as a buffering agent, pH adjuster, tonicity modifier, and process aid. Its market is driven by formulation volume rather than proprietary pricing. Demand is stable to moderately growing, supported by generic drugs, injectable products, biologics manufacturing, oral solid doses, and laboratory reagents.

The product has limited standalone financial disclosure. Manufacturers generally report phosphate chemicals, excipients, or specialty ingredients within broader business segments rather than publishing revenue for sodium phosphate, dibasic anhydrous specifically. Financial performance therefore depends on volume, energy costs, phosphoric-acid economics, qualification status, and the supplier’s ability to sell pharmaceutical-grade material rather than commodity-grade phosphate.

What is sodium phosphate, dibasic anhydrous used for in pharmaceuticals?

Sodium phosphate, dibasic anhydrous is the water-free form of disodium phosphate, commonly identified by CAS No. 7558-79-4. It is also known as disodium hydrogen phosphate anhydrous or DSP anhydrous.

Its main pharmaceutical functions are:

• Buffering acidic or basic formulations
• Adjusting formulation pH
• Modifying ionic strength and tonicity
• Supporting dissolution and chemical stability
• Controlling pH during manufacturing
• Acting as a component of phosphate-buffered systems

The anhydrous form is relevant where water content, stability, weight uniformity, or formulation concentration must be tightly controlled. Hydrated forms, including disodium phosphate dihydrate and heptahydrate, may be substituted in some applications, but they are not interchangeable without recalculating the phosphate and sodium content.

Typical dosage-form applications include:

• Tablets and capsules
• Oral powders and solutions
• Injections and parenteral formulations
• Ophthalmic preparations
• Bioprocessing buffers
• Diagnostic reagents
• Cell-culture and laboratory media

Excipient selection depends on grade, endotoxin controls, elemental impurities, particle properties, residual moisture, microbial limits, and the intended route of administration.

How large is the sodium phosphate, dibasic anhydrous market?

No authoritative public market series isolates sodium phosphate, dibasic anhydrous from broader sodium phosphate, pharmaceutical excipient, or specialty phosphate categories. Published market reports generally combine several phosphate salts, including monosodium phosphate, trisodium phosphate, potassium phosphates, calcium phosphates, and food-grade products. Their estimates are therefore not reliable measures of the addressable market for the anhydrous dibasic pharmaceutical grade.

The commercial market is best characterized as a niche within a large, mature phosphate-chemical supply chain:

Market characteristic	Assessment
Product maturity	Mature, commoditized excipient
Demand base	Broad and recurring
Primary growth driver	Growth in finished pharmaceutical production
Pricing power	Low to moderate
Qualification burden	Moderate to high for regulated formulations
Switching risk	Low after approval; higher before qualification
Manufacturing complexity	Low to moderate
Regulatory differentiation	Limited for standard compendial grades
Public revenue visibility	Low
Biosimilar exposure	None as a direct patent category

Volume demand is likely to grow broadly in line with pharmaceutical production, particularly generic oral solid doses and sterile manufacturing. Revenue growth can diverge from volume because the product is exposed to raw-material, freight, packaging, energy, and quality-assurance costs.

What are the main demand drivers for sodium phosphate, dibasic anhydrous?

Generic and branded drug manufacturing

Sodium phosphate, dibasic anhydrous is used in many formulations that do not depend on a single innovator product. Generic-drug production creates recurring demand across multiple manufacturers and jurisdictions. The excipient is usually a small percentage of the finished product’s bill of materials, limiting its effect on finished-drug pricing but preserving baseline demand.

Injectable and sterile formulations

Phosphate buffers are used in selected injectable and ophthalmic products. Sterile applications require tighter control over bioburden, endotoxins, particulate matter, and trace metals. These requirements support higher prices for qualified pharmaceutical grades and make supplier replacement more difficult.

Biologics and bioprocessing

Phosphate buffers are used in process development, purification, formulation, and analytical workflows. Growth in monoclonal antibodies, vaccines, recombinant proteins, and cell-based products supports demand for high-purity phosphate salts. However, bioprocessing buyers may use specialized buffer systems or concentrated liquid buffers, which can reduce the growth available to a dry anhydrous excipient.

Formulation flexibility

The excipient can be used in direct formulation and as part of phosphate-buffer systems. Manufacturers may choose between anhydrous and hydrated sodium phosphate based on water activity, process conditions, supplier availability, and the final concentration required.

How does sodium phosphate, dibasic anhydrous compare with hydrated sodium phosphate?

The commercial comparison is primarily technical rather than patent-driven.

Attribute	Dibasic anhydrous	Dibasic dihydrate or heptahydrate
Water of crystallization	None by chemical definition	Present
Moisture sensitivity	Lower intrinsic crystal water, but still hygroscopic under some conditions	Higher handling and assay-conversion considerations
Use case	Moisture-sensitive formulations and precise dry-dose control	Common buffer and solution applications
Molecular-weight calculation	Based on anhydrous salt	Requires hydrate-specific calculation
Storage	Requires protection from humidity	Requires controlled humidity and temperature
Substitution	Requires formulation review and assay adjustment	Requires formulation review and assay adjustment
Commercial pricing	Often higher per kilogram than commodity hydrated material	Often broader commodity availability
Regulatory impact	Separate material identity and specifications	Separate material identity and specifications

Anhydrous material can command a premium where it reduces formulation variability or supports a validated process. That premium is limited when customers can qualify a hydrate or another buffer system without changing the product’s regulatory filing.

What is the FDA regulatory status of sodium phosphate, dibasic anhydrous?

Sodium phosphate, dibasic anhydrous is an established pharmaceutical excipient and is listed in the FDA Inactive Ingredient Database for approved drug products. The FDA database records excipient use by route, dosage form, and maximum potency, but inclusion does not constitute blanket approval for every formulation or administration route.[1]

Relevant regulatory controls include:

• Compliance with applicable USP-NF monograph requirements
• Identity and assay testing
• Water and loss-on-drying controls
• pH and solution appearance
• Chloride and sulfate limits
• Heavy metals or elemental-impurity controls
• Microbial and endotoxin controls where applicable
• GMP manufacturing and batch traceability
• Change-control documentation
• Supplier qualification and audit support

The United States Pharmacopeia identifies sodium phosphate, dibasic anhydrous as a compendial material. European and other national pharmacopoeial requirements may apply depending on the customer’s market and the registered product.[2]

For products administered parenterally, the material’s chemical compliance is only one part of qualification. Customers may require dedicated production controls, low endotoxin specifications, validated cleaning, particulate testing, and a detailed supply-chain history.

What patents protect sodium phosphate, dibasic anhydrous?

The core chemical composition is old and is not protected by a meaningful modern composition-of-matter patent estate. Sodium phosphate, dibasic anhydrous is a simple inorganic salt with established industrial and pharmaceutical uses.

IP category	Commercial relevance
Composition-of-matter patents	No meaningful current exclusivity expected
Product-by-process patents	Possible in narrow cases, but weak against conventional production
Pharmaceutical formulation patents	May cover a finished drug using phosphate buffer, not the excipient itself
Manufacturing patents	Possible for specialized purification, crystallization, or particle engineering
Method-of-use patents	May cover a drug product or treatment method, not routine excipient use
Orange Book listings	Not applicable to the standalone excipient
Paragraph IV challenges	Not applicable to the standalone excipient
Biosimilar litigation	Not applicable
Trade secrets	Relevant to process control, purification, and customer specifications

A finished pharmaceutical product can have patents covering a formulation that includes sodium phosphate, dibasic anhydrous. Those patents generally protect the combination, concentration range, delivery system, or therapeutic use. They do not prevent another supplier from manufacturing the excipient for unrelated products.

Are sodium phosphate, dibasic anhydrous products listed in the Orange Book?

No standalone Orange Book exclusivity applies to the excipient. The FDA Orange Book lists approved drug products and certain patent and exclusivity information associated with those products, not ordinary pharmaceutical raw materials.[3]

A formulation containing sodium phosphate, dibasic anhydrous may be listed as a finished drug product, but the excipient does not create:

• New chemical entity exclusivity
• Five-year regulatory exclusivity
• Three-year clinical-investigation exclusivity
• Orphan-drug exclusivity
• Pediatric exclusivity
• Standalone patent protection under the Orange Book

Generic entrants therefore face the patents and regulatory exclusivities of the finished drug, not the excipient’s chemical identity.

When does sodium phosphate, dibasic anhydrous lose exclusivity?

It has no relevant product exclusivity period to lose. The material is a long-established excipient available from multiple chemical and pharmaceutical-grade suppliers.

The commercial barriers are qualification-based:

1. The supplier must manufacture to the relevant compendial standard.
2. The customer must approve the supplier and manufacturing site.
3. The material must pass route-specific quality requirements.
4. The customer must assess the regulatory impact of supplier or process changes.
5. The supplier must maintain consistent particle, moisture, impurity, and microbiological profiles.

These barriers create practical customer retention but do not create legal exclusivity. A qualified alternative supplier can compete once it satisfies the buyer’s technical and regulatory requirements.

Which companies supply pharmaceutical-grade sodium phosphate, dibasic anhydrous?

The supply base includes global chemical companies, excipient distributors, laboratory suppliers, and specialty manufacturers. Public catalogs commonly identify products from or distributed by companies such as Merck/Sigma-Aldrich, Avantor, Thermo Fisher Scientific, Spectrum Chemical, and Jost Chemical. Large phosphate producers, including ICL and Prayon, participate in broader phosphate and specialty-ingredient markets, although product availability and pharmaceutical-grade status must be confirmed for each specific site and catalog item.[4]

The commercial distinction is between:

• Laboratory grade
• Food grade
• Industrial grade
• USP-NF or pharmacopoeial grade
• Injectable or low-endotoxin grade
• GMP-supported custom or validated grade

A catalog listing does not establish that a product is suitable for a regulated drug application. Buyers normally require a certificate of analysis, specification sheet, GMP evidence, change-notification terms, audit rights, residual-solvent and elemental-impurity data, and supply-continuity commitments.

What manufacturing and supply-chain barriers affect the market?

Manufacturing begins with phosphate chemistry and typically involves neutralization, purification, crystallization, drying, milling, and packaging. The underlying chemical process is established, but pharmaceutical-grade execution requires more than producing the correct salt.

Key cost and supply variables include:

• Phosphate-rock and phosphoric-acid prices
• Sodium carbonate or sodium hydroxide costs
• Natural-gas and electricity prices
• Water and wastewater treatment
• Drying capacity
• Packaging and humidity control
• Freight and hazardous-material handling
• Site qualification and quality-system overhead
• Batch-release testing
• Inventory requirements for validated customers

The largest technical risk is not chemical scarcity. It is failure to maintain a consistent impurity and physical-property profile. Changes in source phosphate, crystallization conditions, drying temperature, particle size, or packaging can affect a drug manufacturer’s process and stability data.

Geographic concentration can create intermittent risk even when global capacity is adequate. Port disruption, export restrictions, energy shocks, environmental controls on phosphate processing, and plant outages can affect delivered cost and lead times.

How strong is the patent estate for sodium phosphate, dibasic anhydrous?

The patent estate is weak for the standalone excipient and strong only in limited, application-specific contexts.

A practical risk ranking is:

Risk area	Risk level
Patent infringement from manufacturing the standard salt	Low
Paragraph IV litigation	None for the excipient
Biosimilar-related litigation	None
Finished-drug formulation patents	Product-specific
Proprietary particle engineering	Low to moderate
Purification or low-endotoxin process IP	Moderate in narrow applications
Trade-secret leakage	Moderate
Regulatory change-control exposure	Moderate to high
Supplier substitution risk	Moderate

Manufacturers should focus more on quality agreements, specifications, regulatory files, and continuity planning than on freedom-to-operate searches for the basic chemical.

What is the financial trajectory for sodium phosphate, dibasic anhydrous?

The likely financial trajectory is stable volume growth with limited structural margin expansion.

Base case

Revenue grows at a low-single-digit rate, tracking pharmaceutical production and selected bioprocessing applications. Pricing remains competitive, with periodic increases to recover energy, labor, packaging, testing, and logistics costs. Margins are strongest for validated pharmaceutical and low-endotoxin grades.

Upside case

Higher-value growth can arise from:

• Expansion of sterile and ophthalmic manufacturing
• Increased biologics production
• Regional supply-chain diversification
• Dedicated GMP production
• Customer demand for dual sourcing
• Custom particle-size or impurity specifications
• Long-term supply contracts

Downside case

Revenue and margins can weaken if:

• Customers substitute hydrated sodium phosphate
• Formulators switch to citrate, acetate, or other buffers
• Generic-drug price pressure reduces formulation cost
• Industrial phosphate capacity expands faster than pharmaceutical demand
• Raw-material costs fall and pass-through pricing compresses
• A supplier loses a major qualified customer
• Regulatory remediation disrupts a manufacturing site

The product’s profit pool is determined by grade and service level. Commodity material produces thin margins. Pharmaceutical-grade material can support better economics because qualification, documentation, testing, and change-control services increase switching costs.

How does the competitive landscape affect pricing?

Competition is based on delivered cost, quality consistency, regulatory support, and supply reliability. The chemical formula itself offers little differentiation.

A supplier can improve pricing power by offering:

• Multiple validated manufacturing sites
• Regional inventory
• Low-endotoxin and sterile-compatible grades
• Strong change-notification systems
• Customer-specific specifications
• Pharmacopoeial documentation
• Small-batch flexibility
• Regulatory support for global filings

Distributors can capture value through inventory, technical documentation, and local customer service. Producers with upstream phosphate integration may have a cost advantage, while smaller specialty manufacturers can compete through responsiveness and narrow specifications.

Long-term contracts reduce price volatility but may limit upside during shortages. Spot purchases expose customers to price and availability swings and are less suitable for registered products.

What generic entry risks exist for drugs using sodium phosphate, dibasic anhydrous?

The excipient does not materially increase generic-entry risk. Generic competition depends on the finished drug’s active ingredient, formulation, manufacturing process, patents, regulatory exclusivities, and bioequivalence requirements.

Potential formulation-related barriers may exist where the finished product claims:

• A specific phosphate concentration
• A defined pH range
• A stability-enhancing buffer system
• A particular injectable composition
• A controlled-release or modified-release matrix
• A combination of sodium phosphate with other excipients

Those claims must be assessed at the finished-drug level. A generic manufacturer can often use the same excipient, a hydrated equivalent, or another pharmaceutically acceptable buffer if the product meets regulatory requirements.

What licensing deals and settlement agreements affect the excipient?

No major licensing market or patent-settlement structure is associated with sodium phosphate, dibasic anhydrous as a standalone excipient. Licensing and settlement agreements generally relate to finished pharmaceutical products, manufacturing platforms, or proprietary formulation technologies.

Commercial agreements in this market are more likely to involve:

• Supply contracts
• Quality agreements
• Authorized distribution
• Dual-source arrangements
• Site-specific qualification
• Custom manufacturing
• Regulatory-change commitments

These agreements can materially affect supplier revenue but usually remain private and are not reported as pharmaceutical patent settlements.

Key Takeaways

• Sodium phosphate, dibasic anhydrous is a mature pharmaceutical excipient with recurring demand and limited legal exclusivity.
• The principal uses are buffering, pH adjustment, tonicity modification, and process control.
• Public market-size estimates are generally too broad because they combine multiple phosphate salts and grades.
• Financial growth is likely to track pharmaceutical production at a low-single-digit rate, with better margins in GMP, sterile-compatible, and low-endotoxin grades.
• The standalone patent estate is weak. Orange Book listings, Paragraph IV challenges, biosimilar litigation, and regulatory exclusivity do not apply to the excipient itself.
• The main competitive barriers are supplier qualification, impurity control, documentation, batch consistency, and reliable manufacturing capacity.
• Finished-drug formulation patents may cover products containing sodium phosphate, dibasic anhydrous, but they do not ordinarily block independent production of the excipient.
• The highest commercial risks are raw-material volatility, energy costs, supplier concentration, substitution by hydrated phosphate or alternative buffers, and loss of a qualified customer.

FAQs

Is sodium phosphate, dibasic anhydrous the same as disodium phosphate?

Yes. Sodium phosphate, dibasic anhydrous is disodium hydrogen phosphate without water of crystallization. It must be distinguished from disodium phosphate dihydrate and heptahydrate because assay and molecular-weight calculations differ.

Can sodium phosphate, dibasic anhydrous be used in injectable drugs?

It can be used in injectable formulations when the material meets the applicable chemical, microbiological, endotoxin, particulate, and GMP requirements. A general USP-grade certificate alone may not establish suitability for parenteral use.

Does sodium phosphate, dibasic anhydrous require a Drug Master File?

A Drug Master File is not automatically required for every excipient. A supplier may maintain a DMF or provide equivalent regulatory documentation, depending on the customer’s filing strategy and the applicable jurisdiction.

What is the main substitute for sodium phosphate, dibasic anhydrous?

The closest substitutes are hydrated forms of dibasic sodium phosphate and other phosphate salts. Citrate, acetate, histidine, and tromethamine buffers may replace phosphate in selected formulations, but substitution requires product-specific development and regulatory assessment.

Is sodium phosphate, dibasic anhydrous exposed to biologic patent risk?

No direct biologic patent risk applies to the excipient. Biologic patent disputes may affect demand from a particular finished-product manufacturer, but they do not create or remove exclusivity for sodium phosphate, dibasic anhydrous.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. Merck. (n.d.). Sodium phosphate dibasic anhydrous product information. https://www.sigmaaldrich.com; Avantor. (n.d.). Sodium phosphate dibasic anhydrous product information. https://www.avantorsciences.com; Jost Chemical Co. (n.d.). Sodium phosphate products. https://www.jostchemical.com